adefovir dipivoxil indications/contra

Stem definitionDrug idCAS RN
antivirals 88 142340-99-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • adefovir dipivoxil
  • hepsera
  • preveon
inhibitor of African swine fever virus
  • Molecular weight: 501.48
  • Formula: C20H32N5O8P
  • CLOGP: 1.40
  • LIPINSKI: 2
  • HAC: 13
  • HDO: 1
  • TPSA: 166.98
  • ALOGS: -2.90
  • ROTB: 15

Drug dosage:

DoseUnitRoute
10 mg O

Approvals:

DateAgencyCompanyOrphan
March 6, 2003 EMA
Sept. 20, 2002 FDA GILEAD

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteomalacia 2233.14 89.76 270 998 241 3384350
Fanconi syndrome acquired 1352.18 89.76 175 1093 372 3384219
Hypophosphataemia 1326.83 89.76 204 1064 1990 3382601
Drug resistance 904.51 89.76 164 1104 4499 3380092
Osteoporosis 663.28 89.76 127 1141 4638 3379953
Blood phosphorus decreased 638.53 89.76 97 1171 824 3383767
Renal impairment 425.20 89.76 113 1155 18148 3366443
Fanconi syndrome 392.32 89.76 58 1210 394 3384197
Renal tubular disorder 389.20 89.76 66 1202 1163 3383428
Bone pain 363.11 89.76 88 1180 9673 3374918
Viral load increased 322.33 89.76 53 1215 763 3383828
Blood alkaline phosphatase increased 321.05 89.76 81 1187 10472 3374119
Blood creatinine increased 284.28 89.76 86 1182 21732 3362859
Arthralgia 284.17 89.76 111 1157 60750 3323841
Viral mutation identified 271.83 89.76 44 1224 569 3384022
Hepatic cancer 271.15 89.76 53 1215 2093 3382498
Hepatitis B DNA increased 243.94 89.76 35 1233 185 3384406
Gait disturbance 230.96 89.76 78 1190 27914 3356677
Back pain 207.64 89.76 78 1190 37927 3346664
Aminoaciduria 202.43 89.76 26 1242 46 3384545
Proteinuria 192.73 89.76 46 1222 4660 3379931
Pathogen resistance 192.33 89.76 37 1231 1334 3383257
Multiple fractures 186.77 89.76 33 1235 736 3383855
Bone density decreased 185.05 89.76 36 1232 1377 3383214
Drug ineffective 183.72 89.76 100 1168 115990 3268601
Hepatitis B 176.82 89.76 38 1230 2395 3382196
Glycosuria 159.06 89.76 26 1242 356 3384235
Genotype drug resistance test positive 156.64 89.76 24 1244 210 3384381
Alanine aminotransferase increased 152.65 89.76 55 1213 23585 3361006
Glucose urine present 146.71 89.76 24 1244 330 3384261

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC J05AF08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA EPC N0000175656 Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
FDA Chemical/Ingredient N0000175459 Nucleoside Analog
FDA MoA N0000009947 Nucleoside Reverse Transcriptase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:36044 antiviral drug

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Kidney disease contraindication 90708001 DOID:2527
Lactic acidosis contraindication 91273001 DOID:3650
Steatosis of liver contraindication 197321007 DOID:9452
Toxic nephropathy contraindication 236514003
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Drug Resistance to Anti-retroviral Therapy contraindication

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.73 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG HEPSERA GILEAD N021449 Sept. 20, 2002 RX TABLET ORAL 6451340 July 23, 2018 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA polymerase subunit gamma-1 Enzyme WOMBAT-PK
Protein P Polyprotein INHIBITOR CHEMBL CHEMBL

External reference:

scroll-->
IDSource
4021357 VUID
N0000179520 NUI
C0540694 UMLSCUI
CHEMBL484 ChEMBL_ID
6GQP90I798 UNII
7313 INN_ID
106941-25-7 SECONDARY_CAS_RN
DB00718 DRUGBANK_ID
CHEMBL922 ChEMBL_ID
N0000179520 NDFRT
N0000148776 NDFRT
009377 NDDF
205746 MMSL
398898002 SNOMEDCT_US
16958 MMSL
141400 RXNORM
4021357 VANDF
409114008 SNOMEDCT_US
60871 PUBCHEM_CID
C053001 MESH_SUPPLEMENTAL_RECORD_UI
C106812 MESH_SUPPLEMENTAL_RECORD_UI
CHEBI:31175 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
ADEFOVIR DIPIVOXIL HUMAN PRESCRIPTION DRUG LABEL 1 42794-003 TABLET 10 mg ORAL ANDA 19 sections
Hepsera HUMAN PRESCRIPTION DRUG LABEL 1 46014-0501 TABLET 10 mg ORAL NDA 20 sections
Hepsera HUMAN PRESCRIPTION DRUG LABEL 1 61958-0501 TABLET 10 mg ORAL NDA 20 sections